{"disease":{"id":"niemann-pick-disease","name":"niemann pick disease"},"drugs":{"marketed":[{"drug_id":"olipudase-alfa-rpcp","indication_name":"Niemann-Pick disease, type A","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"XENPOZYME","generic_name":"OLIPUDASE ALFA-RPCP","company_name":"GENZYME CORP","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"olipudase-alfa-rpcp","indication_name":"Niemann-Pick disease, type B","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"XENPOZYME","generic_name":"OLIPUDASE ALFA-RPCP","company_name":"GENZYME CORP","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":34,"revenue":null,"mechanism":""},{"drug_id":"arimoclomol","indication_name":"Niemann-Pick disease type C (NPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Miplyffa","generic_name":"ARIMOCLOMOL","company_name":"Zevra Denmark","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Miplyffa works by activating heat shock proteins to help protect cells from damage."},{"drug_id":"levacetylleucine","indication_name":"Niemann-Pick disease type C (NPC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aqneursa","generic_name":"LEVACETYLLEUCINE","company_name":"Intrabio","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":46,"revenue":null,"mechanism":"Aqneursa works by modifying the activity of a specific enzyme involved in the breakdown of fatty substances in the body."},{"drug_id":"miglustat","indication_name":"Niemann-Pick disease, type C","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavesca","generic_name":"MIGLUSTAT","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"Glucosylceramide Synthase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05368038","title":"ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":100000,"lead_sponsor_name":"Albert Einstein College of Medicine","has_results":false},{"nct_id":"NCT03655223","title":"Early Check: Expanded Screening in Newborns","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":30000,"lead_sponsor_name":"RTI International","has_results":false},{"nct_id":"NCT00344331","title":"Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C","phase":"","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT06985212","title":"National Multicentre Study of the Natural History of Acid Sphingo-myelinase Deficiency in Adults and Children","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"Wladimir MAUHIN, Dr","has_results":false},{"nct_id":"NCT02171104","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":149,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07054515","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":147,"lead_sponsor_name":"Azafaros A.G.","has_results":false},{"nct_id":"NCT05641103","title":"PREDIGA 2: Spanish Acronym of \"Educational and Diagnostic Project for Gaucher and ASMD\"","phase":"","overall_status":"COMPLETED","enrollment_count":122,"lead_sponsor_name":"Fundación Española de Hematología y Hemoterapía","has_results":false},{"nct_id":"NCT05588167","title":"Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT04469894","title":"Health Insurance Literacy and Challenges in Accessing Health Services in Niemann-Pick","phase":"","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"National Niemann-Pick Disease Foundation","has_results":false},{"nct_id":"NCT05642221","title":"Functional Near-Infrared Spectroscopy (fNIRS) Combined With Diffuse Correlation Spectroscopy (DCS) in Neurocognitive Disease as Compared to Healthy Neurotypical Controls","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":false},{"nct_id":"NCT07082725","title":"A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Azafaros A.G.","has_results":false},{"nct_id":"NCT04958642","title":"Adrabetadex to Treat Niemann-Pick Type C1 (NPC1) Disease","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Mandos LLC","has_results":true},{"nct_id":"NCT02612129","title":"Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"ZevraDenmark","has_results":true},{"nct_id":"NCT03883750","title":"Induced Pluripotent Stem Cells for Niemann Pick Disease","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT03759639","title":"N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"IntraBio Inc","has_results":true},{"nct_id":"NCT00316498","title":"Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03643562","title":"Niemann-Pick Type C Treatment With Adrabetadex for Symptoms of Brain and Nervous System","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Mandos LLC","has_results":true},{"nct_id":"NCT07399704","title":"A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":21,"lead_sponsor_name":"Azafaros A.G.","has_results":false},{"nct_id":"NCT03201627","title":"Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Disease","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","has_results":false},{"nct_id":"NCT03910621","title":"Safety and Efficacy of Miglustat in Chinese NPC Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Actelion","has_results":false},{"nct_id":"NCT02939547","title":"Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":13,"lead_sponsor_name":"Cyclo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02912793","title":"Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":12,"lead_sponsor_name":"Cyclo Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06192576","title":"A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)","phase":"","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT03471143","title":"Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT03887533","title":"Combined Intrathecal and Intravenous VTS-270 Therapy for Liver and Neurological Disease Associated With Niemann-Pick Disease, Type C1","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","has_results":true},{"nct_id":"NCT03879655","title":"Open-label Study of VTS-270 in Participants With Neurologic Manifestations of Niemann-Pick Type C1","phase":"PHASE2, PHASE3","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Mandos LLC","has_results":true},{"nct_id":"NCT04189601","title":"Complement Activation in the Lysosomal Storage Disorders","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Melbourne Health","has_results":false},{"nct_id":"NCT01306604","title":"Biomarker for Niemann Pick Type C Disease (BioNPC)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false},{"nct_id":"NCT04316637","title":"Early Access Program With Arimoclomol in US Patients With NPC","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"ZevraDenmark","has_results":false}],"total":29},"guidelines":[],"source":"Drug Landscape verified database"}